To date, there are no specific clinical trials targeting p53 in HCC, but several molecules are being tested for the treatment of solid tumors: ASTX295 (NCT03975387), HDM201 (NCT04116541), idasanutlin MT (NCT04589845), and milademetan MT (NCT0512397), which are small molecules that inhibit MDM2’s activity; PC14586 (NCT04585750) and arsenic trioxide MT (NCT04869475), two small molecules that target mutant p53; and Ad-p53, a p53-based gene therapy (NCT03544723). Here, TP53 is linked to hepatocellular carcinoma.